ClinicalTrials.gg
Active, not recruitingNCT06547385Updated Oct 22, 2026

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

A Phase 1 interventional study of ONO-4578 and ONO-4538 in Colorectal Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jan 2021, registered Aug 2024).
Updated Oct 22, 2026Sponsor changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 174 studies in Colorectal Neoplasms with a site in Japan — 38 open to participants now, 67 under way, 14 of them phase 3. Colorectal Neoplasms · Japan.

Enrollment
136th of 160
40 · median 198
Started
2021
with 14 others
Phase 1
41 of 174
10 open now
Primary completion
2027-10
later than 27 of 66 live
Registered
144th of 174
by date

Among the 174 studies in Colorectal Neoplasms with a site in Japan, this one is the 136th largest by enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2021, is one of 41 in phase 1, reaches primary completion later than 27 of the 66 other live ones, and was the 144th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

38 of the 174 studies in Colorectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Colorectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unresectable colorectal cancer
  • of at least 3 months
  • Patients with performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients with severe complication
  • Patients are unable to swallow oral medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ONO-4578+ONO-4538+XELOX plus bevacizumab

    Drug: ONO-4578 · Drug: ONO-4538 · Drug: Capecitabine · Drug: Oxaliplatin · Drug: Bevacizumab

  • Experimental
    ONO-4578+ONO-4538+FOLFOX plus bevacizumab

    Drug: ONO-4578 · Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Fluorouracil · Drug: Calcium Levofolinate Hydrateb · Drug: Bevacizumab

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Nivolumab

  • Specified dose on specified days

    Also known as: XELODA

  • Specified dose on specified days

    Also known as: ELPLAT

  • Specified dose on specified days

    Also known as: 5-FU

  • Specified dose on specified days

    Also known as: ISOVORIN

  • Specified dose on specified days

    Also known as: AVASTIN

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs and SAEs

    Time frame: up to 3years

  2. Incidence and severity of clinical laboratory abnormalities

    Time frame: up to 3years

  3. 12-lead electrocardiography (Heart rate)

    Time frame: up to 3years

  4. 12-lead electrocardiography (PR interval)

    Time frame: up to 3years

  5. 12-lead electrocardiography (RR interval)

    Time frame: up to 3years

  6. 12-lead electrocardiography (QRS width)

    Time frame: up to 3years

  7. 12-lead electrocardiography (QT interval)

    Time frame: up to 3years

  8. Chest X-ray test

    Time frame: up to 3years

  9. ECOG performance status

    Time frame: up to 3years

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: up to 3years

  2. Disease control rate (DCR)

    Time frame: up to 3years

  3. Overall survival (OS)

    Time frame: up to 3years

  4. Progression-free survival (PFS)

    Time frame: up to 3years

  5. Duration of response (DOR)

    Time frame: up to 3years

  6. Time to response (TTR)

    Time frame: up to 3years

  7. Best oveall response (BOR)

    Time frame: up to 3years

  8. Percentage of change in the sum of tumor diameters of target lesions

    Time frame: up to 3years

  9. Maximum percent change in the sum diameters of the target lesions

    Time frame: up to 3years

  10. Time course of tumor markers

    Time frame: up to 3years

  11. Plasma ONO-4578 concentration

    Time frame: up to 3years

  12. Serum ONO-4538 concentration

    Time frame: up to 3years

  13. Anti-ONO-4538 antibody

    Time frame: up to 3years

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Oct 2027, 81 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 81 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 9, 2024
StartActual
Jan 13, 2021
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 Japan)
  • Kobe City Hospital Organization Kobe City Medical Center General Hospital · Kobe, Japan
  • Kanagawa Cancer Center · Yokohama, Japan
  • NHO Osaka National Hospital · Osaka, Japan
  • Osaka General Medical Center · Osaka, Japan
Show 4 removed
  • Kobe City Hospital Organization Kobe City Medical Center General Hospital · Kobe-shi, Japan
  • Kanagawa Cancer Center · Yokohama-shi, Japan
  • NHO Osaka National Hospital · Osaka-shi, Japan
  • Osaka General Medical Center · Osaka-shi, Japan
Oct 22, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Japan)
    • Kobe City Hospital Organization Kobe City Medical Center General Hospital · Kobe, Japan
    • Kanagawa Cancer Center · Yokohama, Japan
    • NHO Osaka National Hospital · Osaka, Japan
    • Osaka General Medical Center · Osaka, Japan
    Show 4 removed
    • Kobe City Hospital Organization Kobe City Medical Center General Hospital · Kobe-shi, Japan
    • Kanagawa Cancer Center · Yokohama-shi, Japan
    • NHO Osaka National Hospital · Osaka-shi, Japan
    • Osaka General Medical Center · Osaka-shi, Japan
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 4 other changes: index terms, identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06547385
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jan 13, 2021
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion